VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses

What happened: Viking Therapeutics reported a third-quarter 2026 loss of $1.55 per share versus the Zacks Consensus Estimate of a $1.00 loss, with no revenue. Higher operating expenses drove the wider loss. Key numbers: Loss of $1.55 per share vs. Why it matters: CEO Brian Lian said the company is about two and a half years from a potential VK2735 launch, while phase III VANQUISH studies are expected to finish in 2027. VKTX carries a Zacks Rank #3 (Hold). Market: +1.0% today ($21.35), +68.6% YTD, 1.4x vol — as of 20:17 UTC

Viking Therapeutics reported a third-quarter 2026 loss of $1.55 per share versus the Zacks Consensus Estimate of a $1.00 loss, with no revenue. Higher operating expenses drove the wider loss.

CEO Brian Lian said the company is about two and a half years from a potential VK2735 launch, while phase III VANQUISH studies are expected to finish in 2027. VKTX carries a Zacks Rank #3 (Hold). Market: +1.0% today ($21.35), +68.6% YTD, 1.4x vol — as of 20:17 UTC